Germany· DE-A57-f50eca815af3b4ae

Yocon-Glenwood

A yohimbine product containing yohimbine hydrochloride, registered in Germany by Cheplapharm Arzneimittel Gmbh. The same ATC class is registered in 4 of our 19 countries.

ATC G04BE04

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedYocon-GlenwoodATCG04BE04REGISTER NO.DE-A57-f50eca815af3b4…PACKS LISTED0CHECKEDSeptember 30, 2026

Where it is registered

Yohimbine is registered in 4 of 19 countries.

Countries holding a registration under ATC G04BE04 (yohimbine), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 2 of them publish a price we can compare per daily dose

Yohimbine · ATC G04BE04

4 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Germany
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

EMA Article 57 (European Union)
Active substance
Yohimbine Hydrochloride
Manufacturer
Cheplapharm Arzneimittel Gmbh
Country
Germany (DE)
ATC code
G04BE04
ATC class
Yohimbine
Defined daily dose
15 mg, O
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

9 interactions on record for yohimbine.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Yohimbine · interactions on record

9 records

  • 2 severe
  • 5 moderate
  • 2 minor

Most severe, free to view

  • Iobenguane (123I)V09IX01severe
  • Iobenguane (131I)V09IX02severe
  • LorcaserinA08AA11moderate
  • TroglitazoneA10BG01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Yohimbine in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All yohimbine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Austria · Yocon-Glenwood
  • Belgium · Yocoral
  • France · Yocoral
  • Luxembourg · Yocoral

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/93e4adf0-c23e-4def-ab6a-2b5597548380
GET /v1/drugs/93e4adf0-c23e-4def-ab6a-2b5597548380?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Oral Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Yohimbine Hydrochloride",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about yohimbine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.